Clinical Trial

Predicting Psychotic Relapse Using Speech-Based Early Detection

Study acronym: MOTS+
Recruiting
View on ClinicalTrials.gov →
Summary
Psychotic disorders, including schizophrenia and affective psychosis, are severe mental health conditions marked by recurrent episodes that contribute to long-term disability. Relapses, characterized by the re-emergence of psychotic symptoms after remission, are a critical factor in the progression of these disorders, increasing risks such as suicide, cognitive impairment, and unemployment. This study aims to develop a novel, speech-based digital model to predict relapses in individuals with psychosis. Building on previous research into language abnormalities in schizophrenia, the study will employ a longitudinal design across Early Psychosis Intervention (EPI) clinics in Ontario and Quebec to advance relapse prediction
Trial Details
NCT Number NCT06978894
Lead Sponsor Douglas Mental Health University Institute
Conditions Psychosis
Enrollment 250 participants
Start Date 2024-05-27
Primary Completion 2028-07-01 (estimated)
Study Completion 2029-07-01 (estimated)
Updated on ClinicalTrials.gov 2025-05-18